Efficacy and safety of CAR T‐cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition

Abstract Patients with relapsed or refractory (r/r) primary central nervous system (CNS) lymphoma (PCNSL) or secondary central nervous system (CNS) lymphoma (SCNSL) face a dismal prognosis. They have been excluded from most clinical CAR T‐cell trials as investigators feared an increased risk for sev...

Descrición completa

Detalles Bibliográficos

Principais autores:	Anna Ossami Saidy, Christophe Peczynski, Catherine Thieblemont, Michael Daskalakis, Marc Wehrli, David Beauvais, Jürgen Finke, Elisabeth Schorb, Peter Vandenberghe, Philipp Berning, Matthias Stelljes, Francis Ayuk, Ron Ram, Malte Von Bonin, Peter Dreger, Wolfgang Bethge, Andrea Kuhnl, Lasse Jost, Friedrich Stölzel, Bastian vonTresckow, Christoph Renner, Stephan Fuhrmann, Jacques‐Emmanuelle Galimard, Eva Michel, Ali Bazarbachi, Anna Sureda Balari, Norbert Schmitz, Bertram Glass
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2025-05-01
Series:	HemaSphere
Acceso en liña:	https://doi.org/10.1002/hem3.70146
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!